|Day Low/High||98.17 / 98.85|
|52 Wk Low/High||58.59 / 99.36|
Celgene Corporation (NASDAQ: CELG) today announced two updates for ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the treatment of metastatic triple-negative breast cancer and early stage pancreatic cancer.
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for ozanimod for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS).
Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.
However, the RMPIA did not see as much improvement last month as some other market indices.
Celgene Corporation (NASDAQ:CELG) today announced the U.S.
Experts offer their top stock ideas in oncology detection and treatment.
Celgene shares traded sharply lower Thursday after one of Bristol-Myers Squibb's key investors said it $74 billion takeover bid for the cancer drug specialist was too risky and expensive.
Celgene Corporation (NASDAQ:CELG) today announced that the U.S.
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
The RMPIA rose 10.5% during the first half of the current quarter.
Former Attorney General of Louisiana Charles C. Foti, Jr.
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
Hedge fund Starboard Value took a stake in the company last month, a Bloomberg report says.
Jim Cramer reacts to Starboard's stake in Bristol-Myers Squibb and Papa Johns.
Here's what Jim Cramer thinks about Google's earnings, Starboard's investments and Tesla's acquisition.
Jim Cramer weighs in on Starboard's investments, Tesla's purchase and Alphabet's earnings.
News follows Bristol-Myers Squibb's planned $74 billion buy of Celgene. TheStreet.com could not verify the report.
RMPIA soared 9.9% for the month, led by 11 double-digit gainers.
U.S. stocks look set for a mixed open Thursday, amid the busiest reporting session of the earnings season, even as global markets extend gains after the Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.
Many see the Fed as done for the year. Never assume. Read the words as they are written.
Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2018.
Global stocks extended gains Thursday, with markets in Asia rising to the highest level in four months, after the U.S. Federal Reserve signaled a pause in its rate hike plans and a series of blue-chip companies posted stronger-than-expected earnings and profit guidance that eased concerns over the prospect of a damaging slowdown in China.
Bristol-Myers Squibb posts stronger-than-expected fourth-quarter earnings but pulls an application to the U.S. Food and Drug Administration for a blockbuster cancer drug combination in order to collect more data.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
Big pharma is shaping up to be a consolidating category in 2019.
Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes. Plus, he's got your game plan.
Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.